Skip to main content
Top
Published in: Annals of Surgical Oncology 10/2009

Open Access 01-10-2009 | Gastrointestinal Oncology

Prognostic Value of Postoperative CEA Clearance in Rectal Cancer Patients with High Preoperative CEA Levels

Authors: Jeong Yeon Kim, MD, Nam Kyu Kim, MD, Seung Kook Sohn, MD, Yong Wan Kim, MD, Kim Jin Soo Kim, MD, Hyuk Hur, MD, Byung Soh Min, MD, Chang Hwan Cho, MD

Published in: Annals of Surgical Oncology | Issue 10/2009

Login to get access

Abstract

Purpose

We determined the prognostic value of carcinoembryonic antigen (CEA) clearance after tumor resection with serial evaluation of postoperative CEA levels in rectal cancer.

Methods

Between 1994 and 2004, we retrospectively reviewed 122 patients with rectal cancer whose serum CEA levels were measured on the preoperative day and postoperative days 7 and 30. Patients with preoperative CEA levels <5.0 ng/ml were excluded. An exponential trend line was drawn using the three CEA values. Patients were categorized into three groups based on R2 values calculated through trend line, which indicates the correlation coefficient between exponential graph and measured CEA values: exponential decrease group (group 1: 0.9 < R2 ≤ 1.0), nearly exponential decrease group (group 2: 0.5 < R2 ≤ 0.9), and randomized clearance group (group 3: 0.5 ≤ R2). We then analyzed the CEA clearance pattern as a prognostic indicator.

Results

With a median follow-up of 57 months, the 5-year overall survival was 62.3% vs. 48.1% vs. 25% and the 5-year disease-free survival was 58.6% vs. 52.7% vs. 25% among groups 1, 2, and 3 (P = 0.014, P = 0.027, respectively) in patients with stage III rectal cancer. For those with stage II rectal cancer, the 5-year overall survival rate of group 1 was significantly better than groups 2 and 3 (88.8% vs. 74.1%, respectively, P = 0.021).

Conclusions

The postoperative pattern of CEA clearance is a useful prognostic determinant in patients with rectal cancer. Patients with a randomized pattern of CEA clearance after tumor resection should be regarded as having the possibility of a persistent CEA source and may require consideration of intensive follow-up or adjuvant therapy.
Literature
1.
go back to reference Hutter RV. At last–worldwide agreement on the staging of cancer. Arch Surg. 1987;122:1235–9.PubMed Hutter RV. At last–worldwide agreement on the staging of cancer. Arch Surg. 1987;122:1235–9.PubMed
2.
go back to reference Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg. 2002;236:416–21.CrossRefPubMed Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg. 2002;236:416–21.CrossRefPubMed
3.
go back to reference Merkel S, Mansmann U, Papadopoulos T, et al. The prognostic inhomogeneity of colorectal carcinomas Stage III: a proposal for subdivision of Stage III. Cancer. 2001;92:2754–9.CrossRefPubMed Merkel S, Mansmann U, Papadopoulos T, et al. The prognostic inhomogeneity of colorectal carcinomas Stage III: a proposal for subdivision of Stage III. Cancer. 2001;92:2754–9.CrossRefPubMed
4.
go back to reference Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998;58:1149–58.PubMed Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998;58:1149–58.PubMed
5.
go back to reference Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer. 2001;85:692–6.CrossRefPubMed Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer. 2001;85:692–6.CrossRefPubMed
6.
go back to reference McDermott U, Longley DB, Johnston PG. Molecular and biochemical markers in colorectal cancer. Ann Oncol. 2002;13:235–45.PubMed McDermott U, Longley DB, Johnston PG. Molecular and biochemical markers in colorectal cancer. Ann Oncol. 2002;13:235–45.PubMed
7.
go back to reference Han SJ, Yoo S, Choi SH, et al. Actual half-life of alpha-fetoprotein as a prognostic tool in pediatric malignant tumors. Pediatric Surg Int. 1997;12:599–602.CrossRef Han SJ, Yoo S, Choi SH, et al. Actual half-life of alpha-fetoprotein as a prognostic tool in pediatric malignant tumors. Pediatric Surg Int. 1997;12:599–602.CrossRef
8.
go back to reference Walhof CM, Van Sonderen L, Voûte PA, et al. Half-life of alpha-fetoprotein in patients with a teratoma, endodermal sinus tumor, or hepatoblastoma. Pediatric Hematol Oncol. 1988;5:217–27.CrossRef Walhof CM, Van Sonderen L, Voûte PA, et al. Half-life of alpha-fetoprotein in patients with a teratoma, endodermal sinus tumor, or hepatoblastoma. Pediatric Hematol Oncol. 1988;5:217–27.CrossRef
9.
go back to reference D’Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376–83.PubMed D’Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376–83.PubMed
10.
go back to reference Spiess PE, Lee AK, Leibovici D, et al. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer. 2006;107:275–80.CrossRefPubMed Spiess PE, Lee AK, Leibovici D, et al. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer. 2006;107:275–80.CrossRefPubMed
11.
go back to reference Choi JS, Min JS. Significance of postoperative serum level of carcinoembryonic antigen (CEA) and actual half life of CEA in colorectal cancer patients. Yonsei Med J. 1997;38:1–7.PubMed Choi JS, Min JS. Significance of postoperative serum level of carcinoembryonic antigen (CEA) and actual half life of CEA in colorectal cancer patients. Yonsei Med J. 1997;38:1–7.PubMed
12.
go back to reference Arnaud JP, Koehl C, Adloff M. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum. 1980;23:141–4.CrossRefPubMed Arnaud JP, Koehl C, Adloff M. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum. 1980;23:141–4.CrossRefPubMed
13.
go back to reference Behr TM, Sharkey RM, Juweid MI, et al. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. Cancer Res. 1996;56:1805–16.PubMed Behr TM, Sharkey RM, Juweid MI, et al. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. Cancer Res. 1996;56:1805–16.PubMed
14.
go back to reference Fletcher RH. Carcinoembryonic antigen. Ann Intern Med. 1986;104:66–73.PubMed Fletcher RH. Carcinoembryonic antigen. Ann Intern Med. 1986;104:66–73.PubMed
15.
go back to reference Yoshimasu T, Maebeya S, Suzuma T, et al. Disappearance curves for tumor markers after resection of intrathoracic malignancies. Int J Biol Markers. 1999;14:99–105.PubMed Yoshimasu T, Maebeya S, Suzuma T, et al. Disappearance curves for tumor markers after resection of intrathoracic malignancies. Int J Biol Markers. 1999;14:99–105.PubMed
16.
go back to reference Harrison LE, Guillem JG, Paty P, et al. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg. 1997;185:55–9.PubMed Harrison LE, Guillem JG, Paty P, et al. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg. 1997;185:55–9.PubMed
17.
go back to reference Moertel CG, O’Fallon JR, Go VL, et al. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer. 1986;58:603–10.CrossRefPubMed Moertel CG, O’Fallon JR, Go VL, et al. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer. 1986;58:603–10.CrossRefPubMed
18.
go back to reference Slentz K, Senagore A, Hibbert J, et al. Can preoperative and postoperative CEA predict survival after colon cancer resection? Am Surg. 1994;60:528–31.PubMed Slentz K, Senagore A, Hibbert J, et al. Can preoperative and postoperative CEA predict survival after colon cancer resection? Am Surg. 1994;60:528–31.PubMed
19.
go back to reference Wolmark N, Fisher B, Wieand HS, et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg. 1984;199:375–82.CrossRefPubMed Wolmark N, Fisher B, Wieand HS, et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg. 1984;199:375–82.CrossRefPubMed
20.
go back to reference Park YA, Lee KY, Kim NK, et al. Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol. 2006;13:645–50.CrossRefPubMed Park YA, Lee KY, Kim NK, et al. Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol. 2006;13:645–50.CrossRefPubMed
Metadata
Title
Prognostic Value of Postoperative CEA Clearance in Rectal Cancer Patients with High Preoperative CEA Levels
Authors
Jeong Yeon Kim, MD
Nam Kyu Kim, MD
Seung Kook Sohn, MD
Yong Wan Kim, MD
Kim Jin Soo Kim, MD
Hyuk Hur, MD
Byung Soh Min, MD
Chang Hwan Cho, MD
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0651-x

Other articles of this Issue 10/2009

Annals of Surgical Oncology 10/2009 Go to the issue